Guardant Health stock surges on colon cancer blood test news
Covered by 2 sources · 2 articles
2 outlets - including Yahoo and Thestreet - are covering this story. Guardant Health (GH) investors have a new number to think about this week. Bernstein SocGen Group raised its price target on the cancer-screening company's stock to $200 a share, up from $175. Bernstein also kept its Outperform rating intac…
All coverage
Guardant Health stock surges on colon cancer blood test news
Guardant Health stock surges on colon cancer blood test news
Guardant Health (GH) investors have a new number to think about this week. Bernstein SocGen Group raised its price target on the cancer-screening company's stock to $200 a share, up from $175. Bernstein also kept its Outperform rating intac…